Blood cancers

Aussie real-world cohort reaffirms ASCT survival benefit in ‘older’ patients but many miss out

Real-world data has reaffirmed ASCT survival benefit, including in ‘older’ patients but only 60% of multiple myeloma patients aged 65-70 years received a transplant, new data from the Australian and New Zealand myeloma and related diseases registry (MRDR) shows. The latest analysis to come from the registry looked at utilisation and 12-month follow-up outcomes for ...

Already a member?

Login to keep reading.

© 2021 the limbic